"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective Randomized non inferiority Trial involving adult patients undergoing elective surgery under general anesthesia.56 Patients will be enrolled in 2 groups : full dose sugammadex vs half dose sugammadex for reversal of NMB.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: American University of Beirut Medical Center
• Treatments: Glycopyrrolate; Neostigmine; Rocuronium

Criteria

Inclusion Criteria:

• Patients aged 18-70

• ASA class I, II, and III

• undergoing surgery under balanced general anesthesia requiring the use of muscle relaxants throughout the surgery

Exclusion Criteria:

• patients undergoing emergency surgeries

• pregnant patients

• patients with end stage renal disease or chronic kidney disease(GFR less than 60)

• patients with allergy to sugammadex or who had previous complications or side effects from previous sugammadex administration

• patients' refusal

• patients with allergy to recuronium